HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00791167

A Study of the Dose Proportionality of Extended Release Paliperidone

Medication studyAges 18–55Schizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study clarity

Study information

Study start dateJune 2006
Recruitment status
Completed
Enrollment listed in the registry
58
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Not clearly listed
Age range
From 18 Years to 55 Years
Official registry ID
NCT00791167
Official title
Show the full official title

Evaluation of the Dose Proportionality of Two Dose Strengths (1.5 and 3 mg) of Extended-release Paliperidone After a Single Administration to Healthy Men

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone ER.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies